These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 31539242)
21. Feature-Based Molecular Networking for the Targeted Identification of G Hanke W; Patt J; Alenfelder J; Voss JH; Zdouc MM; Kehraus S; Kim JB; Grujičić GV; Namasivayam V; Reher R; Müller CE; Kostenis E; Crüsemann M; König GM J Nat Prod; 2021 Jul; 84(7):1941-1953. PubMed ID: 34197116 [TBL] [Abstract][Full Text] [Related]
22. Cell-permeable high-affinity tracers for G Kuschak M; Namasivayam V; Rafehi M; Voss JH; Garg J; Schlegel JG; Abdelrahman A; Kehraus S; Reher R; Küppers J; Sylvester K; Hinz S; Matthey M; Wenzel D; Fleischmann BK; Pfeifer A; Inoue A; Gütschow M; König GM; Müller CE Br J Pharmacol; 2020 Apr; 177(8):1898-1916. PubMed ID: 31881095 [TBL] [Abstract][Full Text] [Related]
23. Applying Molecular Networking for the Detection of Natural Sources and Analogues of the Selective Gq Protein Inhibitor FR900359. Reher R; Kuschak M; Heycke N; Annala S; Kehraus S; Dai HF; Müller CE; Kostenis E; König GM; Crüsemann M J Nat Prod; 2018 Jul; 81(7):1628-1635. PubMed ID: 29943987 [TBL] [Abstract][Full Text] [Related]
24. Structure-affinity and structure-residence time relationships of macrocyclic Gα Voss JH; Crüsemann M; Bartling CRO; Kehraus S; Inoue A; König GM; Strømgaard K; Müller CE iScience; 2023 Apr; 26(4):106492. PubMed ID: 37091255 [TBL] [Abstract][Full Text] [Related]
25. Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq-Signaling Inhibitor FR900359. Crüsemann M; Reher R; Schamari I; Brachmann AO; Ohbayashi T; Kuschak M; Malfacini D; Seidinger A; Pinto-Carbó M; Richarz R; Reuter T; Kehraus S; Hallab A; Attwood M; Schiöth HB; Mergaert P; Kikuchi Y; Schäberle TF; Kostenis E; Wenzel D; Müller CE; Piel J; Carlier A; Eberl L; König GM Angew Chem Int Ed Engl; 2018 Jan; 57(3):836-840. PubMed ID: 29194875 [TBL] [Abstract][Full Text] [Related]
26. Recommended Tool Compounds: Application of YM-254890 and FR900359 to Interrogate Gα Voss JH ACS Pharmacol Transl Sci; 2023 Dec; 6(12):1790-1800. PubMed ID: 38093837 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice. Kawasaki T; Taniguchi M; Moritani Y; Uemura T; Shigenaga T; Takamatsu H; Hayashi K; Takasaki J; Saito T; Nagai K Thromb Haemost; 2005 Jul; 94(1):184-92. PubMed ID: 16113802 [TBL] [Abstract][Full Text] [Related]
32. The Bacterial G Hanke W; Alenfelder J; Liu J; Gutbrod P; Kehraus S; Crüsemann M; Dörmann P; Kostenis E; Scholz M; König GM J Chem Ecol; 2023 Oct; 49(9-10):549-569. PubMed ID: 37453001 [TBL] [Abstract][Full Text] [Related]
33. Connecting the conformational behavior of cyclic octadepsipeptides with their ionophoric property and membrane permeability. Stadelmann T; Subramanian G; Menon S; Townsend CE; Lokey RS; Ebert MO; Riniker S Org Biomol Chem; 2020 Sep; 18(36):7110-7126. PubMed ID: 32902550 [TBL] [Abstract][Full Text] [Related]
34. Structural response of G protein binding to the cyclodepsipeptide inhibitor FR900359 probed by NMR spectroscopy. Bonifer C; Hanke W; Mühle J; Löhr F; Becker-Baldus J; Nagel J; Schertler GFX; Müller CE; König GM; Hilger D; Glaubitz C Chem Sci; 2024 Aug; 15(32):12939-12956. PubMed ID: 39148790 [TBL] [Abstract][Full Text] [Related]
35. [Pharmacological properties of a specific Gq/11 inhibitor, YM-254890]. Kawasaki T; Uemura T; Taniguchi M; Takasaki J Nihon Yakurigaku Zasshi; 2006 Jul; 128(1):23-31. PubMed ID: 16940696 [No Abstract] [Full Text] [Related]
36. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742 [TBL] [Abstract][Full Text] [Related]
37. Building Chemical Probes Based on the Natural Products YM-254890 and FR900359: Advances toward Scalability. Medcalf MR; Krueger RL; Medcalf ZT; Rosston PA; Zhu Y; Kaltenbronn KM; Blumer KJ; Moeller KD Synthesis (Stuttg); 2023 Jan; 55(1):90-106. PubMed ID: 36644007 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, conformational analysis, and cytotoxicity of new analogues of the natural cyclodepsipeptide jaspamide. Terracciano S; Bruno I; Bifulco G; Copper JE; Smith CD; Gomez-Paloma L; Riccio R J Nat Prod; 2004 Aug; 67(8):1325-31. PubMed ID: 15332850 [TBL] [Abstract][Full Text] [Related]
39. Direct targeting of Gα Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659 [TBL] [Abstract][Full Text] [Related]
40. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. Marco E; Martín-Santamaría S; Cuevas C; Gago F J Med Chem; 2004 Aug; 47(18):4439-52. PubMed ID: 15317456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]